Journal of Asthma and Allergy

PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Pharmaceutical, General Health, Health, FDA, Health Technology, Clinical Trials, Other Health, Online, COPD, Safety, Research, Risk, Death, Link, Efficacy, Journal of Asthma and Allergy, Company, ADULT, Salbutamol, Conference, Papis Loveday, Inhaler, Risk factor, AstraZeneca, Dermatology, Spirometry, Internet, Jean-Jacques Bourdin, MDI, ICS, Science, Diagnosis, Global Initiative for Asthma, Patient, B93, Observational study, Ageing, ERS, BDA, SCS, Chronic lung disease, Week, Biopharmaceutical, Clare Lloyd, CDC, Veni, vidi, vici, Gastroenterology, Hospital, Atmosphere, Medicine, Clinical trial, Growth, NDA, Immunology, AES, ClinicalTrials.gov, Child, Rheumatology, Nature Research, Mortality, Protein Data Bank (file format), Budesonide, ID, Disease, Thomas Ford Chipp, Metabolism, Pharmaceutical industry, Silviculture, Asthma, FEV1, Oncology, Common

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • In March 2018, AstraZeneca and Avillion signed an agreement to advance PT027 through a global clinical development program for the treatment of asthma.
  • Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialize the medicine in the US.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.

AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy

Retrieved on: 
Tuesday, June 7, 2022
Science, Tyrosine kinase inhibitor, OCS, The New England Journal of Medicine, Time, Company, Holgate, Research, Cell, Euronext Paris, Marketing, Allosteric regulation, Survival, Veni, vidi, vici, Inflammation, Suzanne Comhaire-Sylvain, Treatment, University of Oradea, Failure, Maintenance, ERS, University, Clinical & Experimental Allergy, Patient, PKI Resource Query Protocol, Risk, Randomized controlled trial, AMF, Safety, Lists of diseases, Phenotype, AB, MD, B cell, Population, Degenerative disease, Epigenetics of diabetes Type 2, Medicine, PDGFR, Aix-Marseille University, Veterinary medicine, Journal of Asthma and Allergy, Mast cell, Brad Komminsk, Publishing, Pharmaceutical industry, Vaccine, Airline, Masitinib, Asthma

Results from this phase 3 study showed that corticosteroid-dependent severe asthma patients treated with masitinib at 6.0 mg/kg/d had a lower risk of severe asthma exacerbations compared with those in a placebo-control group that did not receive masitinib.

Key Points: 
  • Results from this phase 3 study showed that corticosteroid-dependent severe asthma patients treated with masitinib at 6.0 mg/kg/d had a lower risk of severe asthma exacerbations compared with those in a placebo-control group that did not receive masitinib.
  • Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/d versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.
  • Masitinib significantly decreased the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by OCS.
  • 13 months)
    Masitinib has a unique positioning in severe asthma, in terms of administration (oral administration), mechanism of action, targeted population, and broader eosinophil level.

PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

Retrieved on: 
Sunday, May 15, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Online, BDA, Disease, Metabolism, Medicine, Dermatology, Efficacy, The New England Journal of Medicine, Inhaler, ClinicalTrials.gov, Mortality, AstraZeneca, Conference, Week, Nature Research, NDA, Safety, Biopharmaceutical, Papis Loveday, Immunology, Risk factor, Hospital, SCS, COPD, Protein Data Bank (file format), Clinical trial, Research, Thomas Ford Chipp, ICS, Journal of Asthma and Allergy, CDC, Growth, Death, Company, Budesonide, Salbutamol, Science, MDI, Gastroenterology, Observational study, Rheumatology, Child, Risk, ID, Ageing, Chronic lung disease, Atmosphere, Link, Global Initiative for Asthma, JAMA, Jean-Jacques Bourdin, ERS, Clare Lloyd, Degenerative disease, Diagnosis, Pharmaceutical industry, Silviculture, FEV1, Asthma, Patient

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • AstraZenecas ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
  • Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
  • The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK.